Literature DB >> 29847223

Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy.

Yiming Meng1, Jing Sun1, Tingting Hu2, Yushu Ma1, Tiaozhao Du1, Cuicui Kong1, Guirong Zhang1, Tao Yu3, Haozhe Piao1,4.   

Abstract

Cell-based immunotherapy using natural killer (NK) cells, cytokine-induced killer (CIK) cells and dendritic cells (DCs) is emerging as a potential novel approach in the auxiliary treatment of a tumor. However, non-standard operation procedure, small-scale cell number, or human error may limit the clinical development of cell-based immunotherapy. To simplify clinical scale NK cells, CIK cells and DCs expansions, we investigated the use of the WAVE bioreactor, a closed system bioreactor that utilizes active perfusion to generate high cell numbers in minimal volumes. We developed an optimized rapid expansion protocol for the WAVE bioreactor that produces clinically relevant number of cells for our adoptive cell transfer clinical protocols. The high proliferative rate, surface phenotypes, and cytotoxicity of these immune cells, as well as the safety of cultivation were analyzed to illuminate the effect of WAVE bioreactor. The results demonstrated that the benefit of utilizing modern WAVE bioreactors in cancer immunotherapy was simple, safe, and flexible production.

Entities:  

Keywords:  CIK cells; DCs; NK cells; Tumor immunotherapy; WAVE bioreactor

Mesh:

Year:  2018        PMID: 29847223      PMCID: PMC6284481          DOI: 10.1080/21645515.2018.1480241

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  49 in total

1.  Large-scale growth of the Plasmodium falciparum malaria parasite in a wave bioreactor.

Authors:  John P Dalton; Corine G Demanga; Sarah J Reiling; Juliane Wunderlich; Jenny W L Eng; Petra Rohrbach
Journal:  Int J Parasitol       Date:  2012-02-08       Impact factor: 3.981

Review 2.  Cells as advanced therapeutics: State-of-the-art, challenges, and opportunities in large scale biomanufacturing of high-quality cells for adoptive immunotherapies.

Authors:  Nate J Dwarshuis; Kirsten Parratt; Adriana Santiago-Miranda; Krishnendu Roy
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

Review 3.  The importance of immunization in cancer prevention, treatment, and survivorship.

Authors:  Elizabeth M Ward; Christopher R Flowers; Ted Gansler; Saad B Omer; Robert A Bednarczyk
Journal:  CA Cancer J Clin       Date:  2017-07-28       Impact factor: 508.702

Review 4.  Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Klaus F Rabe
Journal:  N Engl J Med       Date:  2017-08-31       Impact factor: 91.245

Review 5.  Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.

Authors:  Jason Lohmueller; Olivera J Finn
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

Review 6.  Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application.

Authors:  Yiming Meng; Zhifu Yu; Yefeng Wu; Tianzhao Du; Shi Chen; Fanjuan Meng; Nan Su; Yushu Ma; Xiaoxi Li; Sulan Sun; Guirong Zhang
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

7.  Bioreactor engineering using disposable technology for enhanced production of hCTLA4Ig in transgenic rice cell cultures.

Authors:  Jun-Young Kwon; Yong-Suk Yang; Su-Hwan Cheon; Hyung-Jin Nam; Gi-Hong Jin; Dong-Il Kim
Journal:  Biotechnol Bioeng       Date:  2013-04-22       Impact factor: 4.530

8.  Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection.

Authors:  J C M van der Loo; W P Swaney; E Grassman; A Terwilliger; T Higashimoto; A Schambach; C Baum; A J Thrasher; D A Williams; D L Nordling; L Reeves; P Malik
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

Review 9.  Combining radiotherapy with immunotherapy: the past, the present and the future.

Authors:  Evert J Van Limbergen; Dirk K De Ruysscher; Veronica Olivo Pimentel; Damiënne Marcus; Maaike Berbee; Ann Hoeben; Nicolle Rekers; Jan Theys; Ala Yaromina; Ludwig J Dubois; Philippe Lambin
Journal:  Br J Radiol       Date:  2017-05-25       Impact factor: 3.039

10.  The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.

Authors:  Tengfei Zhang; Jing Xie; Seiji Arai; Liping Wang; Xuezhong Shi; Ni Shi; Fen Ma; Sen Chen; Lan Huang; Li Yang; Wang Ma; Bin Zhang; Weidong Han; Jianchuan Xia; Hu Chen; Yi Zhang
Journal:  Oncotarget       Date:  2016-11-08
View more
  4 in total

Review 1.  Recent Advances in Good Manufacturing Practice-Grade Generation of Dendritic Cells.

Authors:  Sarah Cunningham; Holger Hackstein
Journal:  Transfus Med Hemother       Date:  2020-10-28       Impact factor: 3.747

Review 2.  Engineering microenvironments for manufacturing therapeutic cells.

Authors:  Brian J Kwee; Kyung E Sung
Journal:  Exp Biol Med (Maywood)       Date:  2021-07-11

3.  Propofol Promotes Activity and Tumor-Killing Ability of Natural Killer Cells in Peripheral Blood of Patients with Colon Cancer.

Authors:  Dongshui Liu; Xiaoshan Sun; Yue Du; Minmin Kong
Journal:  Med Sci Monit       Date:  2018-09-03

Review 4.  Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.

Authors:  Erica L Heipertz; Evan R Zynda; Tor Espen Stav-Noraas; Andrew D Hungler; Shayne E Boucher; Navjot Kaur; Mohan C Vemuri
Journal:  Front Immunol       Date:  2021-12-01       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.